Because PHESGO is just a different way to give existing treatments, the way PHESGO was studied is a little different than other clinical trials.
The main study was a comparison of PHESGO vs IV PERJETA® (pertuzumab) + Herceptin® (trastuzumab).* This clinical study included 500 people with certain types of HER2-positive early breast cancer. Everyone in the study also received chemotherapy as part of a complete treatment regimen.
The goal of the study was to find out if there were any differences between PHESGO and PERJETA + Herceptin. This study measured the amount of medicine in the bloodstream, which is commonly done to check that the injection works like the infusion. The study also looked at how safe the drug was and if it worked on the cancer.
In this study, no major difference was seen in the amount of medicine that went into the bloodstream with PHESGO compared to PERJETA + Herceptin. The combined results of the study showed no major difference is expected in how it works.
*Some patients in the trial were given Herceptin HYLECTA™ (trastuzumab and hyaluronidase-oysk) injections instead of Herceptin infusions during treatment after surgery.
160 people with HER2+ early breast cancer were asked questions to find out which treatment they preferred. They were given IV PERJETA + Herceptin + chemotherapy before surgery. After surgery, some were given 3 cycles of IV PERJETA + Herceptin then 3 cycles of PHESGO. Others were given PHESGO first then IV PERJETA + Herceptin. Everyone completed a total of 18 cycles of treatment. Patients were asked which treatment they preferred after they completed 6 cycles.
The most common reason people preferred PHESGO was because it took less time in the clinic.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.